Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
- Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024
- Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior year
- European revenues increased 3% for the quarter and 13% for the six months ended September 30, 2023, compared to the same periods prior year
- 該季度的毛利百分比爲36％，比2024年第一財季增長1％
- 截至2023年9月30日的季度和六個月的總運營支出與去年同期相比有所下降
- 與去年同期相比，歐洲的收入在本季度增長了3％，在截至2023年9月30日的六個月中增長了13％
BOULDER, CO / ACCESSWIRE / November 13, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its second fiscal quarter ended September 30, 2023.
科羅拉多州博爾德市/ACCESSWIRE /2023 年 11 月 13 日/ 全球醫療保健領導者索諾瑪製藥公司（納斯達克股票代碼：SNOA）今天公佈了截至2023年9月30日的第二財季的財務業績，該公司開發和生產穩定的次氯酸（HOCl）產品，其應用範圍廣泛，包括傷口、眼部、口腔和鼻腔護理、皮膚病、足病、動物保健和無毒消毒劑。
"In the second quarter of our fiscal year 2024, we continued to reduce costs while maintaining our diligent efforts to expand sales and increase our presence in U.S. and international markets," said Amy Trombly, CEO of Sonoma. "Though our U.S. business saw a decline in consumer sales compared to the prior year, primarily due to softening demand for animal health care products, European revenues have continued to increase, and we see opportunities for further growth and demand for our products both in the U.S. and internationally."
索諾瑪首席執行官艾米·特隆布利表示：“在2024財年的第二季度，我們繼續降低成本，同時繼續努力擴大銷售並增加我們在美國和國際市場的影響力。”“儘管我們的美國業務的消費者銷售額與去年相比有所下降，這主要是由於對動物保健產品的需求疲軟，但歐洲的收入持續增長，我們看到了進一步增長的機會，也看到了美國和國際上對我們產品的需求和進一步增長的機會。”
Business Highlights
業務亮點
Sonoma continued to identify and meet customer needs by introducing new products and expanding distribution:
索諾瑪繼續通過推出新產品和擴大分銷來識別和滿足客戶需求：
- On November 3, 2023, Sonoma launched its intraoperative pulse lavage irrigation treatment in the United States, a new application of its wound care technology developed in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. Hospitals in Europe began trial use of the pulse lavage irrigation treatment, containing Sonoma's Microcyn Technology, in September 2023.
- On August 15, 2023, Sonoma announced that Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel had received the National Eczema Association (NEA) Seal of Acceptance.
- On August 3, 2023, Sonoma announced the establishment of a Scientific Advisory Board, which will serve to inform the company's research and development activities, efforts to address areas of unmet need, and potential new areas of interest.
- 2023 年 11 月 3 日，索諾瑪在美國推出了術中脈衝灌洗療法，這是其傷口護理技術的新應用，旨在滿足人們對可以預防感染和縮短癒合時間的無毒灌洗液的未得到滿足的需求。歐洲的醫院開始試用含有索諾瑪的Microcyn的脈衝灌洗沖洗療法 科技，2023年9月。
- 2023 年 8 月 15 日，索諾瑪宣佈 Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel 已獲得全國溼疹協會 (NEA) 認可印章。
- 2023 年 8 月 3 日，索諾瑪宣佈成立科學顧問委員會，該委員會將爲公司的研發活動、解決未滿足需求領域的努力以及潛在的新興趣領域提供信息。
Results for the Quarter Ended September 30, 2023
截至2023年9月30日的季度業績
Total revenues for the quarter ended September 30, 2023 of $2.7 million decreased by $0.6 million, or 18%, as compared to $3.3 million for the same period last year. Revenues in the United States declined 39% primarily as a result of a decline in animal health over-the counter demand. Revenues in Europe increased 3% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues decreased in Asia and increased in Rest of World when compared to the same period last year. These revenues tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.
截至2023年9月30日的季度總收入爲270萬美元，與去年同期的330萬美元相比減少了60萬美元，下降了18％。美國的收入下降了39％，這主要是由於非處方需求導致動物健康下降。由於對索諾瑪產品的需求增加，歐洲的收入與去年同期相比增長了3％。與去年同期相比，亞洲的收入下降，世界其他地區的收入增加。按季度來看，這些收入往往不穩定，這是因爲客戶下了更大但更少的訂單，以便從數量折扣中受益，而在訂購更大數量時，運費也會降低。
During the quarter ended September 30, 2023, Sonoma reported revenues of $2.7 million and cost of revenues of $1.7 million resulting in gross profit of $1.0 million, or 36% of revenue, compared to a gross profit of $1.5 million, or 46% of revenue in the same period last year. The decline is the result of changes in product mix and territories to which products are shipped.
在截至2023年9月30日的季度中，索諾瑪公佈的收入爲270萬美元，收入成本爲170萬美元，毛利爲100萬美元，佔收入的36％，而去年同期的毛利爲150萬美元，佔收入的46％。下降是產品組合和產品運送地區變化的結果。
Total operating expenses during the quarter ended September 30, 2023 were $2.2 million decreased as compared to the same period in the prior year.
截至2023年9月30日的季度，總運營支出與去年同期相比減少了220萬美元。
Results for the Six Months Ended September 30, 2023
截至2023年9月30日的六個月業績
Total revenues for the six months ended September 30, 2023 of $6.2 million decreased by $1.1 million, or 16%, as compared to $7.3 million for the same period last year. In the six months ended September 30, 2023, Sonoma sold machinery to a customer in Latin America for $750,000, which management expects to be a one-time event. Excluding that event, revenue for the six months ended September 30, 2023 decreased by $0.4 million, or 6%, compared to the same period last year. Revenues in the United States declined 24% primarily as a result of a decline in animal health over-the-counter demand. Revenues in Europe increased 13% compared to the same period last year as the result of increased demand for Sonoma's products. Revenues decreased in Asia and Rest of World when compared to the same period last year. These revenues tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.
截至2023年9月30日的六個月中，總收入爲620萬美元，與去年同期的730萬美元相比減少了110萬美元，下降了16％。在截至2023年9月30日的六個月中，索諾瑪以75萬美元的價格向拉丁美洲的一位客戶出售了機器，管理層預計這將是一次性的。不包括該事件，截至2023年9月30日的六個月收入與去年同期相比減少了40萬美元，下降了6％。美國的收入下降了24％，這主要是由於動物健康非處方藥需求的下降。由於對索諾瑪產品的需求增加，歐洲的收入與去年同期相比增長了13％。與去年同期相比，亞洲和世界其他地區的收入有所下降。按季度來看，這些收入往往不穩定，這是因爲客戶下了更大但更少的訂單，以便從數量折扣中受益，而在訂購更大數量時，運費也會降低。
During the six months ended September 30, 2023, Sonoma reported revenues of $6.2 million and cost of revenues of $4.0 million resulting in gross profit of $2.2 million, or 36% of revenue, compared to a gross profit of $3.2 million, or 44% of revenue in the same period last year. The decline is the result of the sale of machinery in Latin America in 2022, which management expects to be a one-time event, and changes in product mix and territories to which products are shipped.
在截至2023年9月30日的六個月中，索諾瑪公佈的收入爲620萬美元，收入成本爲400萬美元，毛利爲220萬美元，佔收入的36％，而去年同期的毛利爲320萬美元，佔收入的44％。下降是2022年拉丁美洲機械銷售的結果，管理層預計這將是一次性事件，以及產品組合和產品運送地區的變化。
Total operating expenses during the six months ended September 30, 2023 were $4.6 million decreased as compared to the same period in the prior year.
在截至2023年9月30日的六個月中，總運營支出與去年同期相比減少了460萬美元。
Net loss for six months ended September 30, 2023 of $2.9 million increased by $1.0 million, or 52%, when compared to a net loss of $1.9 million for the six months ended September 30, 2023. The increase in net loss is primarily related to the one-time event equipment sale in Latin America in 2022 as well as the factors discussed above. EBITDA loss for the six months ended September 30, 2023 of $2.0 million increased $0.4 million, compared to an EBITDA loss of $1.6 million for the same period last year.
截至2023年9月30日的六個月淨虧損爲290萬美元，增加了100萬美元，增長了52％，而截至2023年9月30日的六個月淨虧損爲190萬美元。淨虧損的增加主要與2022年拉丁美洲的一次性活動設備銷售以及上述因素有關。截至2023年9月30日的六個月中，息稅折舊攤銷前利潤虧損200萬美元，增加了40萬美元，而去年同期的息稅折舊攤銷前利潤虧損爲160萬美元。
As of September 30, 2023, Sonoma had cash and cash equivalents of $2.1 million.
截至2023年9月30日，索諾瑪的現金及現金等價物爲210萬美元。
About Sonoma Pharmaceuticals, Inc.
關於索諾瑪製藥公司
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company has its corporate headquarters in Boulder, Colorado as well as manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at . For partnership opportunities, please contact busdev@sonomapharma.com.
Sonoma Pharmicals是開發和生產穩定的次氯酸 (HOCl) 產品的全球醫療保健領導者，其應用範圍廣泛，包括傷口、眼睛、口腔和鼻腔護理、皮膚病、足病學、動物保健和無毒消毒劑。該公司的產品以安全有效的方式減少感染、瘙癢、疼痛、疤痕和有害的炎症反應。次氯酸 (HOCl) 的體外和臨床研究表明，它具有令人印象深刻的止癢、抗菌、抗病毒和抗炎特性。索諾瑪穩定的HOCl可立即緩解瘙癢和疼痛，殺死病原體並分解生物膜，不會刺痛或刺激皮膚，併爲治療區域的細胞充氧，幫助人體進行自然癒合。該公司的產品直接銷售或通過合作伙伴在全球55個國家銷售，該公司積極尋找新的分銷合作伙伴。該公司的總部位於科羅拉多州的博爾德，在拉丁美洲也有製造業務。歐洲營銷和銷售總部位於荷蘭魯爾蒙德。更多信息可以在以下網址找到。如需合作機會，請聯繫 busdev@sonomapharma.com。
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "reduce," "develop," "aim," and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to the recent pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
前瞻性陳述
除此處的歷史信息外，根據1995年《私人證券訴訟改革法》的 “安全港” 條款，本新聞稿中陳述的事項具有前瞻性，包括有關索諾瑪製藥公司及其子公司（“公司”）的商業和技術進步以及未來財務業績的聲明。這些前瞻性陳述是通過使用 “繼續”、“減少”、“發展”、“目標” 和 “擴大” 等詞語來識別的。本新聞稿中的前瞻性陳述受公司業務固有的某些風險和不確定性的影響，這些風險和不確定性可能導致實際結果發生變化，包括監管臨床和指南開發可能發生變化、科學數據可能不足以滿足監管標準或獲得所需的監管許可或批准、臨床結果可能無法在實際患者環境中複製、公司專利和專利申請提供的保護可能會受到質疑、無效或規避等風險其競爭對手，公司產品的可用市場將不如預期的那麼大，公司的產品將無法進入一個或多個目標市場，收入將不足以滿足公司的現金需求或爲進一步發展提供資金，以及與最近的疫情和經濟發展相關的不確定性、不同國家和城市的產品配方和多種不同的監管和營銷要求，以及公司不時詳細介紹的其他風險向其提交的文件證券交易委員會。除非法律要求，否則公司不承擔任何更新這些前瞻性陳述的義務。
Sonoma Pharmaceuticals, Microcyn and Reliefacyn are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
索諾瑪製藥，Microcyn 和 Reliefacyn 是 Sonoma Pharmicals, Inc. 的商標或註冊商標。所有其他商標和服務標誌均爲其各自所有者的財產。
Media and Investor Contact:
媒體和投資者聯繫人：
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
索諾瑪製藥有限公司
ir@sonomapharma.com
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
索諾瑪製藥有限公司和子公司
簡明合併資產負債表
（以千計，股票金額除外）
| September 30, 2023 | March 31, 2023 | ||||
| (Unaudited) | |||||
ASSETS |
|||||
Current assets: |
|||||
Cash and cash equivalents |
$ | 2,137 | $ | 3,820 | |
Accounts receivable, net |
2,223 | 2,572 | |||
Inventories, net |
2,513 | 2,858 | |||
Prepaid expenses and other current assets |
4,395 | 4,308 | |||
Current portion of deferred consideration, net of discount |
248 | 240 | |||
Total current assets |
11,516 | 13,798 | |||
Property and equipment, net |
433 | 488 | |||
Operating lease, right of use assets |
350 | 418 | |||
Deferred tax asset |
840 | 949 | |||
Deferred consideration, net of discount, less current portion |
421 | 505 | |||
Other assets |
75 | 73 | |||
Total assets |
$ | 13,635 | $ | 16,231 | |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||
Current liabilities: |
|||||
Accounts payable |
$ | 987 | $ | 841 | |
Accrued expenses and other current liabilities |
1,702 | 2,029 | |||
Deferred revenue |
101 | 100 | |||
Deferred revenue Invekra |
61 | 60 | |||
Short-term debt |
172 | 431 | |||
Operating lease liabilities |
216 | 256 | |||
Total current liabilities |
3,239 | 3,717 | |||
Long-term deferred revenue Invekra |
114 | 140 | |||
Withholding tax payable |
4,473 | 4,235 | |||
Operating lease liabilities, less current portion |
134 | 162 | |||
Total liabilities |
7,960 | 8,254 | |||
Commitments and Contingencies |
|||||
Stockholders' Equity |
|||||
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2023 and March 31, 2023, respectively, no shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively |
- | - | |||
Common stock, $0.0001 par value; 24,000,000 shares authorized at September 30, 2023 and March 31, 2023, respectively, 5,179,333 and 4,933,550 shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively |
1 | 5 | |||
Additional paid-in capital |
201,210 | 200,904 | |||
Accumulated deficit |
(192,416) | (189,514) | |||
Accumulated other comprehensive loss |
(3,120) | (3,418) | |||
Total stockholders' equity |
5,675 | 7,977 | |||
Total liabilities and stockholders' equity |
$ | 13,635 | $ | 16,231 | |
| 2023年9月30日 | 2023年3月31日 | ||||
| （未經審計） | |||||
資產 |
|||||
流動資產： |
|||||
現金和現金等價物 |
$ | 2,137 | $ | 3,820 | |
應收賬款，淨額 |
2,223 | 2,572 | |||
庫存，淨額 |
2,513 | 2,858 | |||
預付費用和其他流動資產 |
4,395 | 4,308 | |||
扣除折扣後的遞延對價的當期部分 |
248 | 240 | |||
流動資產總額 |
11,516 | 13,798 | |||
財產和設備，淨額 |
433 | 488 | |||
經營租賃、使用權資產 |
350 | 418 | |||
遞延所得稅資產 |
840 | 949 | |||
遞延對價，扣除折扣，減去流動部分 |
421 | 505 | |||
其他資產 |
75 | 73 | |||
總資產 |
$ | 13,635 | $ | 16,231 | |
負債和股東權益 |
|||||
流動負債： |
|||||
應付賬款 |
$ | 987 | $ | 841 | |
應計費用和其他流動負債 |
1,702 | 2,029 | |||
遞延收入 |
101 | 100 | |||
遞延收入 Invekra |
61 | 60 | |||
短期債務 |
172 | 431 | |||
經營租賃負債 |
216 | 256 | |||
流動負債總額 |
3,239 | 3,717 | |||
長期遞延收入 Invekra |
114 | 140 | |||
應付預扣稅 |
4,473 | 4,235 | |||
經營租賃負債，減去流動部分 |
134 | 162 | |||
負債總額 |
7,960 | 8,254 | |||
承付款和或有開支 |
|||||
股東權益 |
|||||
可轉換優先股，面值0.0001美元；分別於2023年9月30日和2023年3月31日批准了714,286股，截至2023年9月30日和2023年3月31日分別沒有發行和流通的股票 |
- | - | |||
普通股，面值0.0001美元；分別於2023年9月30日和2023年3月31日獲得授權的24,000,000股，分別於2023年9月30日和2023年3月31日發行和流通的5,179,333股和4,933,550股股票 |
1 | 5 | |||
額外的實收資本 |
201,210 | 200,904 | |||
累計赤字 |
(192,416) | (189,514) | |||
累計其他綜合虧損 |
(3,120) | (3,418) | |||
股東權益總額 |
5,675 | 7,977 | |||
負債和股東權益總額 |
$ | 13,635 | $ | 16,231 | |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
索諾瑪製藥有限公司和子公司
綜合虧損簡明合併報表
（以千計，每股金額除外）
（未經審計）
|
Three Months Ended September 30, |
Six Months Ended September 30, |
|||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenues |
$ | 2,731 | $ | 3,331 | $ | 6,158 | $ | 7,314 | ||||||||
Cost of revenues |
1,741 | 1,795 | 3,964 | 4,132 | ||||||||||||
Gross profit |
990 | 1,536 | 2,194 | 3,182 | ||||||||||||
Operating expenses |
||||||||||||||||
Research and development |
536 | 200 | 861 | 406 | ||||||||||||
Selling, general and administrative |
1,662 | 2,067 | 3,781 | 4,362 | ||||||||||||
Total operating expenses |
2,198 | 2,267 | 4,642 | 4,768 | ||||||||||||
Loss from operations |
(1,208 | ) | (731 | ) | (2,448 | ) | (1,586 | ) | ||||||||
Other expense, net |
(90 | ) | (186 | ) | (301 | ) | (253 | ) | ||||||||
Loss before income taxes |
(1,298 | ) | (917 | ) | (2,749 | ) | (1,839 | ) | ||||||||
Income tax expense |
(186 | ) | (100 | ) | (153 | ) | (65 | ) | ||||||||
Net loss |
$ | (1,484 | ) | $ | (1,017 | ) | $ | (2,902 | ) | $ | (1,904 | ) | ||||
Net loss per share: basic and diluted |
$ | (0.29 | ) | $ | (0.33 | ) | $ | (0.57 | ) | $ | (0.61 | ) | ||||
Weighted-average number of shares: basic and diluted |
5,161 | 3,101 | 5,051 | 3,101 | ||||||||||||
Other comprehensive loss |
||||||||||||||||
Net loss |
$ | (1,484 | ) | $ | (1,017 | ) | $ | (2,902 | ) | $ | (1,904 | ) | ||||
Foreign currency translation adjustments |
(213 | ) | (34 | ) | 298 | (99 | ) | |||||||||
Comprehensive loss |
$ | (1,697 | ) | $ | (1,051 | ) | $ | (2,604 | ) | $ | (2,003 | ) | ||||
|
三個月已結束 9月30日 |
六個月已結束 9月30日 |
|||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
收入 |
$ | 2,731 | $ | 3,331 | $ | 6158 | $ | 7,314 | ||||||||
收入成本 |
1,741 | 1,795 | 3,964 | 4,132 | ||||||||||||
毛利 |
990 | 1,536 | 2194 | 3,182 | ||||||||||||
運營費用 |
||||||||||||||||
研究和開發 |
536 | 200 | 861 | 406 | ||||||||||||
銷售、一般和管理 |
1,662 | 2,067 | 3,781 | 4,362 | ||||||||||||
運營費用總額 |
2,198 | 2,267 | 4,642 | 4,768 | ||||||||||||
運營損失 |
(1,208 | ) | (731 | ) | (2,448) | ) | (1,586 | ) | ||||||||
其他費用，淨額 |
(90) | ) | (186) | ) | (301 | ) | (253 | ) | ||||||||
所得稅前虧損 |
(1,298 | ) | (917) | ) | (2,749) | ) | (1,839 | ) | ||||||||
所得稅支出 |
(186) | ) | (100) | ) | (153 | ) | (65) | ) | ||||||||
淨虧損 |
$ | (1,484 | ) | $ | (1,017) | ) | $ | (2,902 | ) | $ | (1,904) | ) | ||||
每股淨虧損：基本虧損和攤薄後 |
$ | (0.29) | ) | $ | (0.33) | ) | $ | (0.57) | ) | $ | (0.61) | ) | ||||
加權平均股票數量：基本股數和攤薄後股數 |
5,161 | 3,101 | 5,051 | 3,101 | ||||||||||||
其他綜合損失 |
||||||||||||||||
淨虧損 |
$ | (1,484 | ) | $ | (1,017) | ) | $ | (2,902 | ) | $ | (1,904) | ) | ||||
外幣折算調整 |
(213 | ) | (34) | ) | 298 | (99 | ) | |||||||||
綜合損失 |
$ | (1,697) | ) | $ | (1,051) | ) | $ | (2,604) | ) | $ | (2,003) | ) | ||||
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands)
(Unaudited)
索諾瑪製藥有限公司和子公司
公認會計准則衡量標準與非公認會計准則衡量標準的對賬
（以千計）
（未經審計）
| Three Months Ended September 30, | Six Months Ended September 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
(1) Net loss adjusted for non-cash items and one-time events or EBITDA loss: |
|||||||||||||||
GAAP net loss as reported |
$ | (1,484 | ) | $ | (1,017 | ) | $ | (2,902 | ) | $ | (1,904 | ) | |||
One-time event adjustment: |
|||||||||||||||
Equipment sale to customer in Latin America (one-time event) |
- | - | - | (400 | ) | ||||||||||
Non-cash adjustments: |
|||||||||||||||
Stock-based compensation |
130 | 113 | 307 | 327 | |||||||||||
Non-cash foreign exchange transaction losses |
108 | 189 | 367 | 256 | |||||||||||
Income tax expense |
186 | 100 | 153 | 65 | |||||||||||
Depreciation and amortization |
45 | 29 | 90 | 59 | |||||||||||
Non-GAAP net loss adjusted for non-cash items and one-time events or EBITDA loss |
$ | (1,015 | ) | $ | (586 | ) | $ | (1,985 | ) | $ | (1,597 | ) | |||
(2) Operating expenses minus non-cash expenses |
|||||||||||||||
GAAP operating expenses as reported |
$ | 2,198 | $ | 2,267 | $ | 4,642 | $ | 4,768 | |||||||
Non-cash adjustments: |
|||||||||||||||
Stock-based compensation |
(130 | ) | (113 | ) | (307 | ) | (327 | ) | |||||||
Depreciation and amortization |
(45 | ) | (29 | ) | (90 | ) | (59 | ) | |||||||
Non-GAAP operating expenses minus non-cash expenses |
$ | 2,023 | $ | 2,125 | $ | 4,245 | $ | 4,382 | |||||||
| 截至9月30日的三個月 | 截至9月30日的六個月 | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
(1) 根據非現金項目和一次性活動調整後的淨虧損或息稅折舊攤銷前利潤虧損： |
|||||||||||||||
報告的 GAAP 淨虧損 |
$ | (1,484 | ) | $ | (1,017) | ) | $ | (2,902 | ) | $ | (1,904) | ) | |||
一次性活動調整： |
|||||||||||||||
向拉丁美洲客戶銷售設備（一次性活動） |
- | - | - | (400 | ) | ||||||||||
非現金調整： |
|||||||||||||||
基於股票的薪酬 |
130 | 113 | 307 | 327 | |||||||||||
非現金外匯交易損失 |
108 | 189 | 367 | 256 | |||||||||||
所得稅支出 |
186 | 100 | 153 | 65 | |||||||||||
折舊和攤銷 |
45 | 29 | 90 | 59 | |||||||||||
根據非現金項目和一次性事件調整後的非公認會計准則淨虧損或息稅折舊攤銷前利潤虧損 |
$ | (1,015) | ) | $ | (586 | ) | $ | (1,985) | ) | $ | (1,597 | ) | |||
(2) 運營費用減去非現金支出 |
|||||||||||||||
報告的 GAAP 運營支出 |
$ | 2,198 | $ | 2,267 | $ | 4,642 | $ | 4,768 | |||||||
非現金調整： |
|||||||||||||||
基於股票的薪酬 |
(130) | ) | (113) | ) | (307) | ) | (327) | ) | |||||||
折舊和攤銷 |
(45) | ) | (29) | ) | (90) | ) | (59) | ) | |||||||
非公認會計准則運營費用減去非現金支出 |
$ | 2,023 | $ | 2,125 | $ | 4,245 | $ | 4,382 | |||||||
| (1) | Net loss adjusted for non-cash items and one-time events, or EBITDA loss, is a non-GAAP financial measure. The Company this as GAAP reported net loss minus depreciation and amortization, stock-based compensation, income taxes, sale of equipment to a Latin America company and non-cash foreign exchange transaction losses. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect normal direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
| (1) | 根據非現金項目和一次性事件調整後的淨虧損或息稅折舊攤銷前利潤虧損是非公認會計准則財務指標。該公司按公認會計原則報告淨虧損減去折舊和攤銷、股票薪酬、所得稅、向拉丁美洲公司出售設備以及非現金外匯交易虧損。公司使用該衡量標準的目的是修改淨虧損，使其僅反映這些支出，以反映衡量期內的正常直接現金交易。不應將非公認會計准則指標視爲根據公認會計原則提出的財務指標的替代品。非公認會計准則指標與其他公司披露的非公認會計准則指標並不總是一致或可比的。 |
| (2) | Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. |
| (2) | 運營費用減去非現金支出是一項非公認會計准則財務指標。公司將運營費用減去非現金支出定義爲GAAP報告的運營費用減去營業折舊和攤銷以及基於股票的營業薪酬。公司使用該衡量標準來確定衡量期內涉及現金交易的總運營費用。不應將非公認會計准則指標視爲根據公認會計原則列報的財務指標的替代品。非公認會計准則指標與其他公司披露的非公認會計准則指標並不總是一致或可比的。 |
SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
PRODUCT RELATED REVENUE SCHEDULES
(In thousands)
(Unaudited)
索諾瑪製藥有限公司和子公司
與產品相關的收入明細表
（以千計）
（未經審計）
The following table shows our consolidated total revenue and revenue by geographic region for the three and six months ended September 30, 2023 and 2022:
下表顯示了截至2023年9月30日和2022年9月30日的三個月和六個月中按地理區域劃分的合併總收入和收入：
|
Three Months Ended September 30, |
||||||||||||||||
(In thousands) |
2023 | 2022 | $ Change | % Change | ||||||||||||
United States |
$ | 590 | $ | 973 | $ | (383 | ) | (39 | %) | |||||||
Europe |
1,201 | 1,170 | 31 | 3 | % | |||||||||||
Asia |
346 | 518 | (172 | ) | (33 | %) | ||||||||||
Latin America |
260 | 394 | (134 | ) | (34 | %) | ||||||||||
Rest of the World |
334 | 276 | 58 | 21 | % | |||||||||||
Total |
$ | 2,731 | $ | 3,331 | $ | (600 | ) | (18 | %) | |||||||
|
三個月已結束 9月30日 |
||||||||||||||||
（以千計） |
2023 | 2022 | $ Change | % 變化 | ||||||||||||
美國 |
$ | 590 | $ | 973 | $ | (383) | ) | (39) | %) | |||||||
歐洲 |
1,201 | 1,170 | 31 | 3 | % | |||||||||||
亞洲 |
346 | 518 | (172 | ) | (33) | %) | ||||||||||
拉丁美洲 |
260 | 394 | (134 | ) | (34) | %) | ||||||||||
世界其他地區 |
334 | 276 | 58 | 21 | % | |||||||||||
總計 |
$ | 2,731 | $ | 3,331 | $ | (600 | ) | (18) | %) | |||||||
|
Six Months Ended September 30, |
||||||||||||||||
(In thousands) |
2023 | 2022 | $ Change | % Change | ||||||||||||
United States |
$ | 1,396 | $ | 1,842 | $ | (446 | ) | (24 | %) | |||||||
Europe |
2,271 | 2,012 | 259 | 13 | % | |||||||||||
Asia |
1,208 | 1,438 | (230 | ) | (16 | %) | ||||||||||
Latin America |
747 | 1,444 | (697 | ) | (48 | %) | ||||||||||
Rest of the World |
536 | 578 | (42 | ) | (7 | %) | ||||||||||
Total |
$ | 6,158 | $ | 7,314 | $ | (1,156 | ) | (16 | %) | |||||||
|
六個月已結束 9月30日 |
||||||||||||||||
（以千計） |
2023 | 2022 | $ Change | % 變化 | ||||||||||||
美國 |
$ | 1,396 | $ | 1,842 | $ | (446 | ) | (24) | %) | |||||||
歐洲 |
2,271 | 2,012 | 259 | 13 | % | |||||||||||
亞洲 |
1,208 | 1,438 | (230) | ) | (16) | %) | ||||||||||
拉丁美洲 |
747 | 1,444 | (697) | ) | (48) | %) | ||||||||||
世界其他地區 |
536 | 578 | (42) | ) | (7) | %) | ||||||||||
總計 |
$ | 6158 | $ | 7,314 | $ | (1,156 | ) | (16) | %) | |||||||
SOURCE: Sonoma Pharmaceuticals, Inc.
來源： 索諾瑪製藥有限公司
譯文內容由第三人軟體翻譯。